Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Theravance Biopharma (TBPH) Equity Average (2016 - 2025)

Historic Equity Average for Theravance Biopharma (TBPH) over the last 12 years, with Q3 2025 value amounting to $228.8 million.

  • Theravance Biopharma's Equity Average rose 2061.09% to $228.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $228.8 million, marking a year-over-year increase of 2061.09%. This contributed to the annual value of $194.3 million for FY2024, which is 4066.23% down from last year.
  • Per Theravance Biopharma's latest filing, its Equity Average stood at $228.8 million for Q3 2025, which was up 2061.09% from $195.4 million recorded in Q2 2025.
  • Over the past 5 years, Theravance Biopharma's Equity Average peaked at $461.2 million during Q4 2022, and registered a low of -$350.6 million during Q2 2022.
  • Over the past 5 years, Theravance Biopharma's median Equity Average value was $189.7 million (recorded in 2024), while the average stood at $58.4 million.
  • As far as peak fluctuations go, Theravance Biopharma's Equity Average tumbled by 8696.76% in 2021, and later soared by 30245.85% in 2023.
  • Quarter analysis of 5 years shows Theravance Biopharma's Equity Average stood at -$331.1 million in 2021, then surged by 239.3% to $461.2 million in 2022, then plummeted by 50.22% to $229.6 million in 2023, then fell by 21.33% to $180.6 million in 2024, then increased by 26.67% to $228.8 million in 2025.
  • Its Equity Average was $228.8 million in Q3 2025, compared to $195.4 million in Q2 2025 and $170.8 million in Q1 2025.